Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
172 results about "Food allergy" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
An abnormal reaction by the immune system following consumption of a certain food.
Method and system for providing dietary information
InactiveUS6980999B1Shorten the timeLow costDigital data processing detailsDiagnostic recording/measuringFood preferenceLife stage
An apparatus, method and data structure for procuring, analyzing, and communicating dietary information, particularly information regarding the research, evaluation and selection of dietary products. The system provides a comprehensive combination of dietary information in a format that facilitates analysis, decision-making, and procurement of various dietary products based on factors, including an individual's medical nutritional needs, current medication(s), cooking skills, budgeted food expense, food preferences, food allergies, life stage, and lifestyle.
Owner:GRANA CLARE
Gluten-free Foods Containing Microalgae
InactiveUS20100297323A1Improve health benefitsDesirable sensory propertySpread compositionsDough treatmentAdditive ingredientCholesterol
Disclosed herein are microalgae-containing gluten-reduced and gluten-free finished food compositions, as well as microalgae-containing food ingredients for the large-scale manufacture of gluten-reduced and gluten-free foods. Foods and ingredients of the invention, while reducing or eliminating gluten, also have increased health benefits through reduction or elimination of less healthy oils and fats via replacement of primarily monounsaturated algal oils. The novel food compositions also possess more desirable sensory properties and shelf life than previously existing gluten free foods. Foods and ingredients disclosed herein, whoch containing reduced or no gluten, also containing high dietary fiber levels, reduced or eliminated cholesterol, and healthier oil content than existing gluten free foods. Also disclosed are methods of reducing food allergies and symptoms of diseases such as Celiac-Sprue to address increasing rates of sensitivity to gluten-containing products. Also disclosed are methods of formulating and manufacturing microalgae-containing gluten-free foods and ingredients for the formulation of such foods.
Owner:CORBION BIOTECH INC
Method of treating mast cell activation-induced diseases with a proteoglycan
InactiveUS6689748B1Decrease in urinaryBiocidePeptide/protein ingredientsInflammatory Bowel DiseasesInterstitial cystitis
The invention provides a method for preventing and treating the harmful biological effects of biochemicals secreted from activated mast cells in the organism of warm blooded animals and more especially human beings, said effects being associated with allergy (including but not limited to allergic conjunctivitis, allergic rhinitis, allergic otitis, asthma, allergic uticaria, food allergy and atopic dermatitis), hyperproliferative diseases such as leukemia and systemic mastocytosis, interstitial cystitis, inflammatory bowel disease, irritable bowel syndrome, osteoporosis and scleroderma. The method consists in administering to said animals and especially to human beings an effective amount of a proteoglycan such as chondroitin sulfate with mast cell secretion inhibitory activity, alone or in combination with one or more synergistic adjuvants such those belonging to the class of flavonoids or compounds with histamine-1 receptor antagonist activity.
Owner:THETA BIOMEDICAL CONSULTING & DEVMENT
Cellular Constituents From Bacteroides, Compositions Thereof, and Therapeutic Methods Employing Bacteroides or Cellular Constituents Thereof
A cellular constituent is lysed from, produced by and / or isolated from one or more bacteria from the genus Bacteroides, and the cellular constituent, a derivative thereof, and / or one or more bacteria from the genus Bacteroides, or a modified form thereof, is employed in compositions and methods for modulating an inflammatory response. Such methods include methods of treating, delaying the onset of or reducing the symptoms of one or more inflammatory conditions / diseases, including corporal or gastrointestinal inflammation, for example, Irritable Bowel Syndrome, Crohn's Disease, or colitis, and / or associated diseases such diabetes, asthma, multiple sclerosis, cancer, rheumatoid arthritis, gingivitis, atopic diseases, for example, hay fever, food allergies, eczema, rhinitis, dermatitis, conjunctivitis, atopic syndrome and keratosis pelaris, ocular inflammatory disease, strokes, cardiovascular disease, depression, atherosclerosis and hypertension, and comprise administering a composition comprising one or more natural and / or modified bacteria of the genus Bacteroides, and / or a cellular constituent lysed from, produced by, or isolated from one or more natural and / or modified bacteria from the genus Bacteroides, or a derivative thereof.
Owner:MOORE RES ENTERPRISES
Compositions and methods for modulation of RORgammat functions
InactiveUS20070154487A1Reduce severityMany symptomSenses disorderNervous disorderAutoimmune conditionScreening method
The present invention relates to expression of RORγt in cells and tissues and the effect of expression of this gene on proliferation of specific immune cells and in promotion of immune cell aggregates and in induction of IL17 producing cells. Furthermore, the invention relates to methods and agents that may decrease function of the gene product (the protein) or expression of this gene in individuals experiencing an inflammatory condition, an autoimmune disease or a food allergy, or any other condition whereby it is desirable to inhibit an immune response. In addition, methods and agents useful for enhancing the function of RORγt with agonists or expression of this gene are also considered for use whereby it is desirable to increase immunity to a pathogen or tumor cell, for example, for use in conjunction with a vaccine. Screening methods for identifying novel modulators (antagonists and agonists) of RORγt are also disclosed.
Owner:NEW YORK UNIV
Method and system for providing dietary information
InactiveUS20060053184A1Low costShorten the timeSpecial data processing applicationsMarketingFood preferenceLife stage
Owner:GRANA CLARE
Computer program, method, and system for monitoring nutrition content of consumables and for facilitating menu planning
InactiveUS20030165799A1Good choiceTotal calories lowData processing applicationsSurgeryDiseaseNutrition
A computer program, method, and system for dynamically and interactively providing nutrition content information for consumables such that a user may monitor, tailor, plan, and review their intake thereof in light of a health-related interest or concern, such as, for example, weight-loss, food allergies, or diabetes or other nutrition affected illnesses or disabilities. Consumables are categorized and displayed in lists associated with an appropriate color to draw attention to relative nutrition content and to facilitate quicker and easier evaluation of a consumable of interest. Summaries are provided of a user's actual intake in light of a pre-established target intake for a particular day. Detailed reports may be generated showing consumption over a user-specifiable time period.
Owner:DYNAMIC NUTRITION SOLUTIONS LLC
TH2-specific gene
InactiveUS6190909B1Increase the number of cellsEffective in number of cellOrganic active ingredientsFungiContact dermatitisTransgene
The present invention relates to the discovery, identification and characterization of nucleic acids that encode a novel protein differentially expressed within the TH2 cell subpopulation (hereinafter referred to as STIF). The invention encompasses STIF nucleotides, host cell expression systems, STIF proteins, fusion proteins, polypeptides and peptides, antibodies to the STIF protein, transgenic animals that express a STIF transgene, or recombinant knock-out animals that do not express the STIF protein, and compounds that modulate STIF gene expression or STIF activity that can be used for diagnosis, drug screening, clinical trial monitoring, and / or used to treat STIF based disorders, such as proliferative disorders and T-lymphocyte-related disorders including, but not limited to, chronic inflammatory diseases and disorders, such as Crohn's disease, reactive arthritis, including Lyme disease, insulin-dependent diabetes, organ-specific autoimmunity, including multiple sclerosis, Hashimoto's thyroiditis and Grave's disease, contact dermatitis, psoriasis, graft rejection, graft versus host disease, sarcoidosis, atopic conditions, such as asthma and allergy, including allergic rhinitis, gastrointestinal allergies, including food allergies, eosinophilia, conjunctivitis, glomerular nephritis, certain pathogen susceptibilities such as helminthic (e.g., leishmaniasis) and certain viral infections, including HIV, and bacterial infections, including tuberculosis and lepromatous leprosy.
Owner:MILLENNIUM PHARMA INC
Cellular constituents from bacteroides, compositions thereof, and therapeutic methods employing bacteroides or cellular constituents thereof
Owner:MOORE RES ENTERPRISES
Antigen detection system and methods of use
InactiveUS20120264232A1Shorten test timePromotes even distributionComponent separationPhase-affecting property measurementsTest foodEngineering
A system and method for testing for the presence of antigens in food stuffs permits a user to test food products for the presence of antigens for a given food allergy that the user may have. The system comprises two main components, a base station and a test well. The user places a sample of food into the test well. A macerator homogenizes the food in the test well. Antibodies to a particular antigen are bound to an antigen detector in the test well. The base station includes a cartridge dock which powers the macerator and the antigen detector. Antigen-antibody binding provides a change detectable by the detector, which signals the base station of the presence of a threshold degree of antigen-antibody binding and alerts the user of the presence of the antigen, such as by a visual or audible indicator.
Owner:ALIMENT HEALTH
Biotype diets system: predicting food allergies by blood type
InactiveUS7601509B2Ultrasonic/sonic/infrasonic diagnosticsAnalysis using chemical indicatorsAntigenRed blood cell
The invention is a diet-typing system for humans, including novel methods for diagnosis and treatment of food allergies and hypersensitivities. The diagnostic method correlates blood types (immunologically reactive antigens on RBC, skin and membranes) to four kinds of food allergies / hypersensitivities (IgE antibodies, IgG antibodies, T-cells, and Lectins). The results are used to identify and predict food allergies and hypersensitivities for six biological types (blood types A1, A2, B, O, A1B, and A2B), plus diet modifications for three subtypes (blood type Rh-negative, males and females). The treatment method uses the results to make food recommendations (to eat, limit, or avoid), based on the strength or classification of allergy scores, to mitigate the risk of food allergies and hypersensitivities in future persons. The diet-typing system presents the results on six diet cards, one for each blood type. The methods and resulting diets are unique, and differ substantially from prior inventions.
Owner:POWER LAURA W
Fusion molecules and treatment of IgE-mediated allergic diseases
InactiveUS20030082190A1Negatively expressionFind utility in the treatmentSenses disorderFungiLate phaseVaccination
The invention concerns bifunctional fusion molecules for the treatment of IgE-mediated allergic conditions and FcepsiRI-mediated autoimmune conditions. The invention provides a new therapeutic approach for the treatment of both acute and late-phase allergic responses due to ingestion, inhalation, cutaneous and parenteral exposure to allergens, responses including asthma, allergic rhinitis, atopic dermatitis, severe food allergies, chronic urticaria and angioedema, as well as anaphylactic reactions due to exposures such as bee stings or penicillin allergy. In addition, the invention provides for a novel, safer and more efficacious form of allergy vaccination.
Owner:RGT UNIV +1
Anti-IgE antibodies
The present invention relates to novel human antibodies specifically directed against human immunoglobulin E (anti-IgE). The present invention also relates to pharmaceutical compositions and methods for treating asthma, in particular allergic asthma, as well as other IgE-mediated disorders including allergic rhinitis and food allergies.
Owner:PFIZER INC +1
Fusion molecules and treatment of IgE-mediated allergic diseases
The invention concerns bifunctional fusion molecules for the treatment of IgE-mediated allergic conditions and FcεRI-mediated autoimmune conditions. The invention provides a new therapeutic approach for the treatment of both acute and late-phase allergic responses due to ingestion, inhalation, cutaneous and parenteral exposure to allergens, responses including asthma, allergic rhinitis, atopic dermatitis, severe food allergies, chronic urticaria and angioedema, as well as anaphylactic reactions due to exposures such as bee stings or penicillin allergy. In addition, the invention provides for a novel, safer and more efficacious form of allergy vaccination.
Owner:RGT UNIV OF MINNESOTA +1
Fukinanolide compounds and pharmaceutical application thereof
InactiveCN1844114ADual activityInhibit lipoxygenaseOrganic chemistryAntipyreticSinusitisWhite blood cell
The invention discloses the structure of four novel bakkenolide compounds extracted from Petasites tricholobus Franch. having a formula (1), the process for extraction and separation, and the use of the compounds in preparing medicament for the treatment and prevention of diseases possibly related to theramine and / or leukotrienes constituents, including asthma, allergic rhinitis, nasal sinusitis, conjunctivitis, food allergy, psoriasis, urticaria, pruritus, eczema, chronic infectious arthritis, enteropathy, nervous disease and otitis.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Pet food for reducing food allergy reactions
InactiveUS20070031534A1Reduce generationEasy to useFood processingAnimal feeding stuffBiotechnologyHypersensitive response
As a pet food produced to contain no proteins that can become allergens, a pet food that contains 1 or more types of amino acids or salts thereof instead of protein raw materials that can become allergens or a pet food produced to contain, in addition to the above amino acid(s), 1 or more types of protein raw materials with low allergenicity selected from any of potato, sweet potato, rice, foxtail millet, barnyard millet, kaoliang, corn, pea, brewer's yeast, and baker's yeast is provided.
Owner:NOSAN CORP +1
Novel Low Allergenic Food Bar
InactiveUS20080085343A1Reduce contentImprove blood sugar controlFruit and vegetables preservationVitamin food ingredientsAutoimmune conditionErgogenic Effects
The subject invention provides novel low allergenic nutrient compositions. Advantageously, the low allergenic food products of the subject invention can be used as a replacement for a snack or meal in cases of hunger or fatigue for individuals diagnosed with a food allergy or degenerative or autoimmune disease, or for use as an ergogenic aid for persons participating in sports or other forms of exercise.
Owner:PETTY HOLLY TASHA +2
Chinese medicinal composition for treating skin itch and preparation method thereof
InactiveCN101810800AImprove self-coordinationFunction increasePowder deliveryAnthropod material medical ingredientsDiseaseMedicine allergy
The invention relates to a Chinese medicinal composition for treating skin itch and a preparation method thereof. The Chinese medicinal composition mainly comprises the following raw material medicaments: figwort root, root of red-rooted salvia, cortex dictamni, natural indigo, divaricate saposhnikovia root, safflower, peach seed, radix rehmanniae preparata, mint, cicada slough, kudzu-vine root, Mongolian snakegourd root, radix rehmanniae preparata, simpleleaf shrub chastetree fruit, reed rhizome, lalang grass rhizome, common lophatherum herb, gardenia, lightyellow sophora root, ash bark, red paeony root, tree peony bark, sinkiang arnebia root, dahurian patrinia herb, glandularstalk St. paulswort herb, erythrina indica lam, tangerine peel, combined spicebush root, areca peel and the like. The Chinese medicinal composition can be prepared into any common oral preparation by the conventional Chinese medicinal preparation method. The Chinese medicinal composition can obviously improve symptoms such as local or general skin itch caused by various skin diseases, food allergy, medicament allergy and the like. The Chinese medicinal composition has the advantages of exact clinical effects, obvious curative effect, quick response, low cost, basically no toxic or side effects and the like.
Owner:TAIYI HEPU BEIJING RES INST OF TCM
Genetic markers of food allergy
ActiveUS7732135B2Increase propensityIncreased propensity to food allergyMicrobiological testing/measurementFermentationIl 4 receptorGenetics
A genetic marker of food allergy is disclosed. The marker comprises variants of IL-4 receptor alpha, IL13 and CD14.
Owner:CHILDRENS HOSPITAL MEDICAL CENT CINCINNATI +1
Mobile Device Supported Medical Information Services
ActiveUS20120293322A1Medical communicationLocal control/monitoringComputerized systemWireless mobile devices
A wireless telecommunications system can receive position information associated with a wireless mobile device of a user and a medical access point name from the wireless mobile device, can determine a gateway based on the position information and the access point name, can receive medical information associated with the user from the wireless mobile device via the gateway, and can provide, based on the medical information and the position information, the medical information to a computer system of a medical facility. The medical information can include drug allergies, food allergies, health issues, physician contact information, emergency contact information, and / or a preferred medical facility, among others. The medical information can be useful in providing medical aid to the user of the wireless mobile device if the user is not able to communicate via verbal means, via written means, and / or via sign means.
Owner:AT&T MOBILITY II LLC
Histamine-releasing factor (HRF), hrf-receptor and methods of modulating inflammation
InactiveUS20130084293A1Shorten the durationReduce frequencyCompound screeningApoptosis detectionHistamine releasing factorHypersensitive response
Methods of treating a food allergy, allergic reactions, hypersensitivity, inflammatory responses, inflammation are provided. In one method, histamine releasing factor (HRF) / translationally controlled tumor protein (TCTP) is contacted with a compound that inhibits or reduces binding of HRF / TCTP to an immunoglobulin in order to treat the food allergy, allergic reaction, hypersensitivity, inflammatory response, or inflammation. Methods of reducing or decreasing the probability, severity, frequency, duration or preventing a subject from having an acute or chronic food allergy, allergic reaction, hypersensitivity, an inflammatory response or inflammation, are also provided. In one method, histamine releasing factor (HRF) / translationally controlled tumor protein (TCTP) is contacted with a compound that inhibits or reduces binding of HRF / TCTP to an immunoglobulin in order to reduce or decrease the probability, severity, frequency, duration or prevent a subject from having an acute or chronic food allergy, allergic reaction, hypersensitivity, an inflammatory response or inflammation.
Owner:LA JOLLA INST FOR ALLERGY & IMMUNOLOGY
Methods For Characterizing Antibody Binding Affinity And Epitope Diversity in Food Allergy
ActiveUS20110071043A1High affinityPeptide librariesPeptide/protein ingredientsEpitope mappingFood allergy
Methods for performing epitope mapping, and for characterizing the antibody binding affinity and epitope diversity of antibodies in a sample using peptide microarray are provided. In some aspects, methods are provided for the specific characterization of IgE and IgG4. Also disclosed are methods for diagnosing whether a milk-allergic individual will outgrow his or her allergy based on the characterization of the individual's milk allergen-specific IgE antibodies.
Owner:MT SINAI SCHOOL OF MEDICINE
Nutritional supplements and methods for primary prevention of food allergies
InactiveUS20170360922A1Allergen ingredientsMultivalent vaccineNutrition supplementationEnvironmental health
The present invention relates to formulations and methods for preventing food allergies in a subject. Embodiments of the invention provide for administration of allergens from eight types of food that cause food allergies in western societies: peanut, tree nuts, milk, egg, soy, wheat, fish, and shellfish. The allergens may be provided directly to the subject, or to the subject's mother, who may be pregnant or nursing.
Owner:TURKE PAUL
Treatment of allergic conditions
Orally administered sodium cromoglycate has been found to be effective in the treatment of allergic conditions such as asthma, general food allergies, ulcerative colitis, atopic eczema, chronic urticaria and irritable bowel syndrome if it is presented such that the sodium cromoglycate becomes bioavailable within 10 minutes of exposure to intestinal fluid. The sodium cromoglycate may be presented as enteric-coated tablets or individually enteric-coated pellets or microgranules packaged with disintegrant in a ratio of at least 1.2:1 disintegrant:sodium cromoglycate (w:w). Optionally, the patients are first selected to have a total serum IgE level of at least 150 iu / ml.
Owner:THORNTON & ROSS
Novel Anti-il 13 antibodies and uses thereof
ActiveUS20110014199A1Relieve symptomsDown-regulate activitySenses disorderAntipyreticUveitisAntiendomysial antibodies
The present invention relates to anti IL13 antibodies that hind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.
Owner:GENENTECH INC
Polycyclic acid compounds useful as crth2 antagonists and antiallergic agents
InactiveCN101636386AHas CRTH2 binding activityOrganic active ingredientsSenses disorderAllergic dermatitisDisease
The present invention relates to a novel compound or a salt thereof, which is useful as a CRTH2 antagonist, especially as a medicament for disorder that participates eosinophil, for example, allergic disorder such as asthma, allergic rhinitis, allergic dermatitis, conjunctival inflammation, hives, eosinophilic bronchitis, food allergy, inflammation of the nasal sinuses, multiple sclerosis, angiitis, or chronic obstructive pulmonary disease (COPD) and the like.
Owner:ASTELLAS PHARMA INC
Food for improving constitutional trait and preparation technology of food
ActiveCN104256616AEasy to manufactureLow costImmunological disordersFood ingredient functionsDiseaseDrug allergy
The invention relates to food, in particular to Food for improving the constitutional trait and a preparation technology of the food. According to the food for improving the constitutional trait, synergy is achieved by efficacy of medicines through reasonable compatibility, so that the food has the functions of improving symptoms such as poor season and climate adaptability, easiness of scratch on skin, proneness to forming of wheal and urticaria, proneness to hay fever, asthma and the like, proneness to trigger of inveterate disease, drug allergy, food allergy and the like for allergic constitution.
Owner:北京王琦医学研究院
Process for producing milk fractions rich in secretory immunoglobulins
InactiveUS20110130545A1Yield easilyHigh yieldMilk preparationMetabolism disorderNasal cavityFiltration
The present invention concerns a process for producing compositions that are rich in secretory IgA (S-IgA) by fractionating milk containing S-IgA. Such compositions may be used in particular for treating and / or preventing infections and / or inflammation of the mucosal surfaces, e.g. the gastro-intestinal tract, urogenital tract, respiratory tract, nasal cavity or oral cavity, treating and / or preventing obesity and related diseases, or treating and / or preventing food allergies in subjects in need of such treatment. Briefly stated, the current invention provides a process for producing milk fractions rich in secretory Immunoglobulin A, using one or more microporous membrane filtration steps. A preferred protocol of the present process involves de-fatting, micro-filtration and ultrafiltration-concentration through a number of diafiltration cycles. The process of the invention, apart from the unexpectedly high yields achievable, offers advantages which are of particular interest in view of the scalability, application in existing diary factories and controllability of process parameters influencing the S-IgA quality and stability.
Owner:W HEALTH LP
Tolerogenic vaccine and method
InactiveUS20060093580A1Increased proliferationBiocidePeptide/protein ingredientsRegulatory T cellAutoimmune condition
Methods and compositions are provided for treating autoimmune diseases such as diabetes, rheumatoid arthritis, inflammatory bowel disease, and other conditions involving undesired immune responses such as allergies, including food allergies, and graft-versus-host disease. In one embodiment disclosed, regulatory / suppressor T cells are selected or expanded in culture using a phospholipase D (PLD) inhibitor to prevent growth of effector T cells and a growth factor to stimulate the regulatory cells. Antigen-specific regulatory / regulatory T cells can be produced by this method. The regulatory T cells can then be administered to a patient in need of suppressive immunotherapy. In another embodiment, PLD inhibitor, growth factor, and an antigen for which antigen-specific suppressive immunotherapy is desired are administered to a patient via injection, oral or topical administration, or other means known to the art.
Owner:MEDICAL COLLEGE OF GEORGIA RES INST
Compositions for protection against superficial vasodilator flush syndrome, and methods of use
InactiveUS20120046237A1Good effectGood water solubilityBiocideOrganic chemistryVascular dilatationPhospholipid
Compositions for protection against SVFS induced by niacin, a carcinoid, mesenteric traction, serotonin, post-menopause, alcohol, monosodium glutamate, mastocytosis, atopic dermatitis, food-allergy or food intolerance, and mast cell activation syndrome, or against individual symptoms of SVFS, superficial vasodilation, feeling of warmth, itching (pruritus) and hives, comprising a flavonoid compound of the structure 2-phenyl-4H-1-benzopyran or 2-phenyl-4-keto-1-benzopyran or glycosides thereof, or chalconoid compounds, with appropriate substitutions of their hydroxyl groups to render them water soluble or in combination with a pshospholipid or cyclodextrin to render them to have higher oral absorption, administered alone or together with an anti-superficial vasodilation dose of one or more of, olive kernel oil, a serotonin inhibitor, a prostaglandin inhibitor, willow bark extract. A composition for treating cardiovascular disease with niacin, but without eliciting the SVFS effects of niacin, has also been invented.
Owner:THETA BIOMEDICAL CONSULTING & DEVMENT
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com